...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Term sheet and enterprise valuation

I am wondering what the possibility during the AGM that DM will elude to a term sheet or LOI from a BP or tell the Shareholders that he has been instructed by the lawyers that nothing can be talked about in public about any partnership any longer , ie finalization part of the deal,  I really doubt it but it would give me just a hint of confidence that DM is not stringing along for yet another year of deal discussions, it is really getting quite old ,  7 years moving the science along and getting only a co development deal to pay the trials , absolutely pathetic ,while the like of Repare therapeutic get An IPO retail investor respect of a $1.8 Billion market, as well as Constellation Pharma with with similar marketcap

come on Donny get it done this time for a similar enterprise valuation rather than these $2us PP to move the science along 

 

 

Share
New Message
Please login to post a reply